Pfizer (PFE, Financial) is stepping up its obesity drug development by naming James List as its new chief internal medicine officer, according to a Friday press release. The former Johnson & Johnson (JNJ, Financial) executive brings extensive expertise from his post?doctoral research in GLP?1 weight loss drugs.
Based in New York, the pharmaceutical giant is refocusing its R&D efforts to fast?track development of cardiovascular, metabolic, hematologic, and obesity treatments. List previously led global therapeutic initiatives at J&J's Janssen unit, emphasizing his background in managing complex drug portfolios.
The move comes as Pfizer intensifies competition in the obesity market, currently dominated by Eli Lilly (LLY, Financial) and Novo Nordisk (NVO, Financial). A recent TD Cowen note indicated that the duopoly is expected to persist until 2030. In 2023, Pfizer discontinued its twice?daily oral obesity regimen due to adverse side effects, shifting attention toward a once?daily formulation now in late?stage development.
The appointment is part of Pfizer's broader strategy to enhance its anti?obesity portfolio and secure a stronger global market presence.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。